Barclays Downgrades Pacira BioSciences to Equalweight From Overweight, Adjusts Price Target to $25 From $38
Pacira BioSciences Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Pacira BioSciences, Maintains $57 Price Target
HC Wainwright & Co. Reiterates Buy on Pacira BioSciences, Maintains $57 Price Target
Pacira BioSciences Analyst Ratings
Barclays Maintains Overweight on Pacira BioSciences, Lowers Price Target to $38
Analyst Ratings For Pacira BioSciences
Needham Adjusts Price Target on Pacira BioSciences to $43 From $45, Keeps Buy Rating
Pacira BioSciences Analyst Ratings
Needham Maintains Buy on Pacira BioSciences, Lowers Price Target to $43
Pacira BioSciences Analyst Ratings
Teva Upgraded at J.P. Morgan on Upcoming Catalysts
Pacira BioSciences Analyst Ratings
Pacira BioSciences Analyst Ratings
RBC Cuts Price Target on Pacira BioSciences to $45 From $53, Keeps Outperform Rating
Pacira BioSciences Analyst Ratings
Pacira BioSciences Analyst Ratings
RBC Cuts Price Target on Pacira BioSciences to $53 From $58, Keeps Outperform Rating
Raymond James Initiates Coverage On Pacira BioSciences With Outperform Rating, Announces Price Target of $42
Pacira BioSciences Analyst Ratings